Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

LORLATINIB vs LOVASTATIN: Which Drug Is Safer?

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

LORLATINIB vs LOVASTATIN: Safety Overview

Metric LORLATINIB LOVASTATIN
Total FAERS Reports 5,508 1,387
Deaths Reported 1,542 204
Death Rate 28.0% 14.7%
Hospitalizations 1,232 287
Average Patient Age 56.5 yrs 60.2 yrs
% Female Patients 54.0% 55.9%
FDA Approval Date Nov 2, 2018 Apr 14, 2006
Manufacturer Pfizer Laboratories Div Pfizer Inc Preferred Pharmaceuticals, Inc.
Route ORAL ORAL
Marketing Status Prescription Discontinued